Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Tectonic Therapeutic (NASDAQ: TECX) reported clinical progress and year-end cash and expense figures. TX45 showed positive Part B Phase 1b topline results with a 29.2% reduction in PCWP and 17.3% improvement in cardiac output. TX45 moved into two Phase 2 trials (PH-ILD opened for screening; APEX topline expected 2026). TX2100 randomized its first healthy volunteer in a Phase 1a trial in Feb 2026. Cash and cash equivalents were $253.8 million as of Dec 31, 2025, providing runway into Q4 2028.

#TECX Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TECX/tectonic-thera...

#TECX Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TECX/tectonic-thera...

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF Tectonic Therapeutic (NASDAQ: TECX) announced positive topline Phase 1b Part B results for TX45 in patients with Group 2 pulmonary hypertension associated with HFrEF on October 29, 2025. In 14 enrolled patients a single IV dose produced meaningful hemodynamic improvements including PCWP -29.2%, TPR -29.2%, mPAP -19.3% and CO +17.3%, with echocardiography showing persistent gains at day 29 (LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3%). TX45 was well tolerated with no serious or severe adverse events reported. Results support potential expansion into PH‑HFrEF while the company continues the APEX Phase 2 trial with topline 2026 readout expected.

#TECX Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

www.stocktitan.net/news/TECX/tectonic-thera...

Leading Indicators, Tuesday September 2, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Tue Sept 2nd - #ZONE #FSI #TECX #MGIC #KITT #IVA #DPRO #CELU #ADN #SMWB - More: crystalequityresearch.com/leading-indi... - #smallcap

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights Tectonic Therapeutic (NASDAQ: TECX) reported Q2 2025 financial results and provided key clinical updates. The company ended Q2 with $287.4 million in cash, projecting runway into Q4'2028. Notable developments include plans to initiate a Phase 2 trial for TX45 in PH-ILD in 2026, completion of enrollment in TX45 Phase 1b Part B trial for PH-HFrEF, and continued enrollment in the TX45 APEX Phase 2 trial.Complete results from TX45 Phase 1b Part A showed promising outcomes, including a 19% reduction in pulmonary capillary wedge pressure and 18.5% improvement in cardiac output. The company's pipeline expansion includes TX2100, targeting hereditary hemorrhagic telangiectasia, with Phase 1 trial initiation expected in Q1'2026.Q2 2025 financial results showed R&D expenses of $17.2 million and a net loss of $20.0 million, reflecting increased investment in clinical development.

#TECX Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TECX/tectonic-thera...

Clinical-Stage Biotech Tectonic Therapeutic Secures Coveted Russell 3000 Index Position Clinical-stage biotech achieves significant market recognition with Russell indexes inclusion. Automatic addition to Russell 1000 or 2000 indices follows. Get details.

#TECX Tectonic Therapeutic Joins Russell 3000® Index

www.stocktitan.net/news/TECX/tectonic-thera...

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights Tectonic Therapeutic (NASDAQ: TECX) reported its Q1 2025 financial results and business updates. The company highlighted positive interim results from its TX45 Phase 1b Part A trial for PH-HFpEF patients, showing a 17.9% reduction in PCWP and >30% reduction in PVR for severe cases. The company successfully completed a $185 million PIPE financing in February 2025, strengthening its cash position to $306.2 million as of March 31, 2025, extending runway into Q4 2028. Tectonic initiated Part B of the TX45 Phase 1b trial in March 2025, with topline results expected in H2 2025. The company reported a net loss of $15.9 million for Q1 2025, with R&D expenses of $13.0 million and G&A expenses of $5.3 million. Full results from the Phase 1b Part A trial will be presented at the ESC Heart Failure Congress on May 17, 2025, while the APEX Phase 2 trial continues with results expected in 2026.

#TECX Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TECX/tectonic-thera...

Insider Buying Week 04-11-25 Every Bear Market Ends with a Tsunami of Insider Buying What a great time to be an insider. Every bear market since 2001 has only ended with a plethora, a […]

a price decline, it's notable.
bit.ly/4jn1uB6
#InsiderBuying #TheInsidersFund #TECX #Biotech #DrugDiscovery

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Tectonic Therapeutic (NASDAQ: TECX) reported Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's TX45 Phase 1b trial showed promising interim results with a 17.9% reduction in Pulmonary Capillary Wedge Pressure in PH-HFpEF patients and over 30% reduction in Pulmonary Vascular Resistance in CpcPH patients.Financial highlights include $141.2 million in cash and cash equivalents as of December 31, 2024, plus $185.0 million from a February 2025 private placement, extending cash runway into Q4'28. Q4 2024 saw increased R&D expenses of $9.2 million (vs $7.1M in Q4 2023) and net loss of $12.4 million (vs $7.9M in Q4 2023).Key upcoming milestones include Phase 1b Part B results expected in 2H'25, APEX Phase 2 trial results in 2026, and TX2100 Phase 1 initiation for HHT treatment in Q4'25 or Q1'26.

#TECX Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/TECX/tectonic-thera...

Over $40M in #TECX insider purchases have been reported so far this February.

#stockmarket #econsky #finsky #insidertrading #insidealert #congresstrading #stocktrading

Major Funding Alert: Tectonic Therapeutic Lands $185M from Elite Investors at Premium Price Tectonic Therapeutic raises $185M through PIPE financing at $50-54/share, backed by prominent investors like Adage Capital and Deep Track Capital, to advance TX45 and TX2100 programs.

#TECX Tectonic Announces $185 Million Private Placement

www.stocktitan.net/news/TECX/tectonic-annou...

Just In: ( NASDAQ: #TECX ) (TECX) Trading Signals

NEWS: ( NASDAQ: #TECX ) Tectonic Therapeutic Reports Positive Interim TX45 Phase 1b Trial Data

Game-Changing Results: This New Drug Could Transform Pulmonary Hypertension Treatment Breakthrough Phase 1b data reveals TX45's dual impact on heart function and pulmonary pressure, with up to 30% improvement in severe cases. Zero serious adverse events reported.

#TECX Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

www.stocktitan.net/news/TECX/tectonic-thera...

#TECX Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

www.stocktitan.net/news/TECX/tectonic-thera...

NEWS: ( NASDAQ: #TECX ) Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

#StockMarket #News